A Safety and Effectiveness Study of Vaccine Therapy in Patients With Indolent Lymphoma
Study Details
Study Description
Brief Summary
Primary Objectives:
-
To document the efficacy of treatment with autologous lymphoma-derived HSPPC-96 of selected patients with indolent lymphoma. The efficacy endpoints are:
-
the rate of complete and partial responses
-
the time to progression.
Secondary Objectives:
-
To evaluate the safety and tolerability of autologous tumor-derived heat-shock protein peptide complex (HSPPC-96) administered intradermally once weekly for four consecutive weeks, followed by HSPPC-96 administered once every two weeks.
-
To evaluate the feasibility of autologous HSPPC-96 preparation from lymphoma specimens.
-
To assess approximately the composition of the tissue source of the autologous HSPPC-96 for each patient.
-
To study the effect of autologous lymphoma-derived HSPPC-96 vaccine therapy on the expression of Fas ligand and TRAIL death proteins in peripheral blood lymphocytes of patients with indolent lymphoma.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Phase 2 |
Study Design
Outcome Measures
Primary Outcome Measures
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patients with previously treated or newly diagnosed follicular center cell grade I or grade II lymphoma, small lymphocytic lymphoma, MALT lymphoma, monocytoid B-cell lymphoma, Waldenstrom's macroglobulinemia, or marginal zone lymphoma with bidimensionally measurable disease;
-
Part of the resected specimen must undergo routine pathologic examination to confirm the diagnosis of lymphoma. The remaining tissue must be used for the preparation of autologous HSPPC-96;
-
Autologous HSPPC-96 vaccine must be successfully prepared and provided by the sponsor;
-
A minimum of 2 grams of non-necrotic, resectable malignant lymphoma for HSPPC-96 preparation;
-
Bidimensionally measurable disease in at least one location other than the resected lymphoid tissue;
-
Life expectancy of at least 16 weeks;
-
Zubrod performance status of less then or equal to 2;
-
Adequate bone marrow function;
-
Adequate hepatic function;
-
Adequate renal function;
-
Signed written informed consent;
-
Patients of child-bearing potential must practice contraception, which is adequate in the opinion of the Principal Investigator;
-
Patients of child-bearing potential must have a negative serum pregnancy test prior to entry into the study and must not be lactating;
-
Patients must be willing to be followed at the M. D. Anderson Cancer Center during the course of treatment and follow-up;
-
Electrocardiogram if none performed in the prior six months;
-
Patients must have no chemotherapy, immunotherapy, radiotherapy, or experimental anti-cancer therapy within six weeks prior to starting autologous HSPPC-96 administration;
-
Patients must have fully recovered from prior anti-cancer therapy;
-
Tumor measurements and staging no more than 4 weeks prior to receiving the first dose of autologous HSPPC-96.
Exclusion Criteria:
-
Patients with active or prior history of central nervous system lymphoma;
-
Patients with serious intercurrent medical illnesses, requiring hospitalization;
-
Patients with a history of primary or secondary immunodeficiency (other than related to the malignant lymphoma because treatment is dependent on functional immune system) or patients taking immunosuppressive drugs such as systemic corticosteroids;
-
Women who are pregnant or lactating;
-
Patients participating in another clinical trial;
-
Patients receiving growth factors of any kind, including G-CSF, GM-CSF, or Epogen;
-
Patients with bulky disease, defined as greater than 10 cm in diameter;
-
Patients with positive HIV antibody;
-
Patients with more than 4 previous treatment regimens will be excluded.
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | M.D. Anderson Cancer Center | Houston | Texas | United States | 77030 |
Sponsors and Collaborators
- Agenus Inc.
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- C-100-09
- MDACC Protocol ID99-354